Glaukos Corporation $GKOS Stock Acquired by Maryland State Retirement & Pension System

Maryland State Retirement & Pension System increased its stake in shares of Glaukos Corporation (NYSE:GKOS) by 53.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,143 shares of the medical instruments supplier’s stock after buying an additional 4,600 shares during the quarter. Maryland State Retirement & Pension System’s holdings in Glaukos were worth $2,158,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. BlackRock Inc. bought a new stake in Glaukos in the second quarter valued at $1,333,318,000. Jupiter Topco LLC acquired a new position in Glaukos during the second quarter worth $679,614,000. Primecap Management Co. CA acquired a new position in Glaukos during the second quarter worth $424,969,000. Janus Henderson Group PLC raised its stake in Glaukos by 77.2% during the first quarter. Janus Henderson Group PLC now owns 5,348,395 shares of the medical instruments supplier’s stock worth $575,844,000 after acquiring an additional 2,329,608 shares in the last quarter. Finally, William Blair Investment Management LLC bought a new position in shares of Glaukos during the second quarter valued at $92,476,000. Institutional investors own 99.04% of the company’s stock.

Glaukos Price Performance

Shares of GKOS traded down $0.43 on Friday, hitting $245.60. The company’s stock had a trading volume of 546,373 shares, compared to its average volume of 1,924,346. The company has a market capitalization of $14.54 billion, a PE ratio of -83.54 and a beta of 0.68. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.57 and a quick ratio of 4.09. Glaukos Corporation has a fifty-two week low of $87.32 and a fifty-two week high of $255.18. The company has a 50 day moving average price of $184.61 and a 200 day moving average price of $147.10.

Glaukos (NYSE:GKOS) last released its quarterly earnings results on Wednesday, October 28th. The medical instruments supplier reported $0.47 EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.57. Glaukos had a negative return on equity of 0.97% and a negative net margin of 24.60%. The business had revenue of $211.03 million for the quarter, compared to analyst estimates of $168.04 million. During the same period in the prior year, the company earned ($0.16) EPS. Glaukos’s revenue for the quarter was up 58.0% on a year-over-year basis. On average, research analysts anticipate that Glaukos Corporation will post 0.50 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Glaukos news, Director Gilbert Kliman sold 2,500 shares of the business’s stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $253.00, for a total value of $632,500.00. Following the transaction, the director owned 37,406 shares of the company’s stock, valued at approximately $9,463,718. The trade was a 6.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 5.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Glaukos in a report on Thursday, October 15th. UBS Group started coverage on shares of Glaukos in a report on Tuesday, July 28th. They issued a “neutral” rating and a $150.00 target price on the stock. Jefferies Financial Group increased their target price on shares of Glaukos from $190.00 to $210.00 and gave the stock a “buy” rating in a research report on Tuesday, September 22nd. Mizuho set a $225.00 target price on shares of Glaukos in a research report on Thursday, October 29th. Finally, BTIG Research lifted their price target on shares of Glaukos from $205.00 to $234.00 and gave the company a “buy” rating in a report on Thursday, October 29th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Glaukos has an average rating of “Moderate Buy” and an average target price of $216.71.

About Glaukos

Glaukos Corporation is an ophthalmic medical technology company that develops and commercializes treatments for glaucoma and other eye disorders. Its portfolio includes minimally invasive glaucoma surgery (MIGS) devices, such as the iStent family, and iDose TR, an implant designed to deliver glaucoma medication inside the eye over an extended period. The company also offers products for corneal disorders, including technology used in corneal cross-linking procedures to treat keratoconus and other conditions that weaken the cornea.